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Abstract 
Background: To study the reasons of acceptability, 
efficacy,short term and long term side effects of 
Levonorgestrel Subdermal implant as long term 
reversible contraceptive. 
Methods:  In this descriptive study women 
(n=13)were counselled regarding Levonorgestrel 
SDI. Levonorgestrel SDI was inserted sub-dermally 
in the upper arm under local anaesthesia. 
Information was collected regarding study specific 
variables. Follow up was performed at 1 and 6 
months and 12,24 and 36 months. 
Results: Maximum number of patients wanting 
levonorgestrel subdermal implants were between 30-
35 years. Majority of women opting for this 
procedure had 3-4 live issues. Majority (44%) of the  
women choose this method based on personal 
information. Most common side effect was heavy 
and irregular vaginal bleeding 18.7% after 6 months, 
and 17.3% after 12 months. Patients advised medical 
treatment for heavy menstrual bleeding did not 
respond well(cyclical progestogens and tranexamic 
acid). Fifteen percent of users got SDI removed by 
end of 12 months, mainly due to above side effects. 
The 3- year cumulative pregnancy rate was zero.  
Conclusion: Levonorgestrel SDI can be an 
acceptable, convenient and effective long term 
reversible contraceptive method. Menstrual 
disturbances and feeling of weight gain are the 
major reported side effects, leading to 
discontinuation of the method.  
Key Words: Long term reversible contraception, 
Levonorgestrel, Irregular vaginal bleeding. 
Introduction 
Pakistan is a developing country with high maternal 
mortality and perinatal mortality and significant 
maternal and child morbidity. This situation can only 
be improved if pregnancies are planned and unwanted 
pregnancies are avoided through promotion of 
appropriate methods of contraception in young 
women. Rapid population growth high rates of 
unintended pregnancies and hazards of unsafe 
abortions are problems faced by developing countries 
like Pakistan.Maternal mortality and morbidity is 
higher in patients without contraception use. 1.  Most 
of the women (75.8 %),in reproductive age, require 
and seek family planning services . 2 
In 2011 Peripert et al proposed that long acting 
reversible contraceptives (LARC) have high efficacy 
and in order to reduce the number of unwanted 
pregnancies clinicians should offer long term 
reversible contraceptives as first line options 3 Recent 
advances in contraception have developed methods 
which are safe, reversible and more easily available. 4. 
Levonorgestrel Subdermal Implants (SCI) were 
introduced nearly 28 years back and are marketed in 
more than 25 countries. Currently they are available in 
Pakistan with Trade name of Jedelle and Sino 
ll.Levonorgestrel SDI are two flexible rods containing 
150 mg of Levonorgestrel which is released slowly 
over 3-4 years causing anovulation, endometrial 
thinning and thickened cervical mucous. 5 These 
implants provide contraception for 3-5 years. 1 
They are inserted by minor surgical procedure where 
two match stick size, soft rods are placed sub-dermally 
in the upper arm under local anaesthesia.4 
Levonorgestrel SDI can be removed any time before 
the specified period on clients wish. This method has 
many advantages e.g. is free from hassle of daily pill 
taking and there is no need of monthly clinical visits as 
in case of injectable contraceptives. SCI becomes active 
in nearly 48 hours after insertion and does not 
interfere with coital activity. They are suitable for 
patients suffering from medical disorders like mild 
hypertension and diabetes and safer regarding 
thromboembolic effects. But they offer no protection 
against sexually transmitted diseases.6 Common side 
effects include irregular menses, breast tenderness, 
headache, dyspepsia and feeling of weight gain. 
Insertion of the implants is done as an outdoor surgical 
procedure. Under aseptic measures and local 
anaesthesia two flexible rods containing 
Levonorgestrel are inserted under the skin of upper 
arm with the help of a trocar. Small aseptic dressing is 
applied to cover the wound. For removal, a small 
incision is made at the lower edge of the inserted rods 
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which then are removed with the help of small artery 
forceps. 7    
 
Subjects and Methods 
This prospective observational study was performed 
at Contraception Clinic, Department of Gynae/Obs,  
Rawal Institute of Health Sciences, Islamabad,from 
July 2014 to December 2017.  Women, 20 to 45 years 
old (n=130), opting for the study were told about its 
purpose,method of insertion and plan of follow up. 
Follow up was performed at 1, 6, 12, 24, and 36 
months interval. Insertion was performed in the minor 
operating theatre. After evaluation patient was 
advised to come on 4th to 5th day of menses. The inner 
side of upper arm was cleaned and draped, under 
local anaesthesia two rods of levonorgestrel subdermal 
implant (Jedelle – Trocar, reference 81075175 Bayer 
Pharma AG.Berlin Germany) were placed under the 
skin 8 cm above the elbow (Figure 1 &2).Women with 
BMI >= 30 Kg/m2,with severe liver disease, with high 
risk for thromboembolism and who were within first 6 
weeks postpartum, were excluded . Clients were 
counselled regarding possible side effects and care of 
insertion site. Follow up was performed in the 
contraceptive clinic or on telephone at specified 
intervals. Women were informed that they can come to 
the clinic any time they need help or treatment. 
 
             
Figure 1&2.  Subcutaneous Levonorgestrel Subdermal 
implant placed   under the skin 8 cm above the elbow 
 
Results 
Mean age of implant users was 32 years, with 
maximum number between 31-35 years. Women 
having 1-4 children were equally interested in the 
method. Majority (38%) had 3-4 children. Weight of 
women ranged from 60-65 kg (Table 1). More than half 
(58.6 %) of the clients were previously using a 
contraceptive method, but wanted a new, safe and 
convenient method (Table 2).Fifty four (42%) adopted  
Levonrgestrel on doctor or health care providers 
advice (Table 3).  The most common short term side 
effect was dyspepsia and loss of appetite (7.7 %), and 
feeling of weight gain (7.7%) . The most common long 
term side effect was heavy menstrual bleeding mostly 
reported at 6 to 12 months by 14% and 
13.3%respectively (Table 4). This was also the major 
cause for removal of SDI. Cumulative pregnancy rate 
over 3 years was zero (Table 4). 
Table 1: Sociodemographic characteristics 
 (n = 130) 
Age / years No  Percentage 
20 - 25 22 17 % 
26 - 30 38 29% 
31 - 35 52 40% 
36 - 40 14 11% 
41 - 45 4  03 % 
Number of live children 
1-2 48 37% 
3-4 50 38% 
5-6 22 17% 
>6 12 09% 
Last child born /years 
<1 56 43% 
1-2 30 23% 
3-4 24 18% 
>5 10 7.6% 
Not known    10 7.6% 
Table 2: Previous Contraception Used By 
Levonorgestrel SDI Users 
Method No Percentage 
Contraceptive pills 16 12% 
Contraceptive injections 18 13% 
Condoms 10 08% 
Withdrawal method - - 
IUCD 32 24% 
None 54 41% 
Table 3: Reason for accepting Levonorgestrel 
SDI (n=130) 
Reason No Percentage 
Doctor’s/ Health-care Provider’s 
Advice 
54 42% 
Personal Decision (information 
through social media, literature, 
etc.) 
57 44% 
Good Experience By Relative / 
Friend 
19 14% 
 
The method  continuation at end of 24 months was 
79%. At 36 months it was 73% (Figure 3). The main 
reason for discontinuation was menstrual problems, 18 
users were unable to tolerate this side effect. The 
second-most common reason for discontinuation was 
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gastric problems (dyspepsia and loss of appetite) 
weight gain resulting in device removal in 3 cases each 
(Table 5) 
 
Table 4: Frequency of side effects over 3 years 
Side Effect 
1 month  
6 
months  
12 
months  
24 
months  
36  
months  
(n= 130) (n= 129) (n= 120) (n= 101) (n=: 94) 
No(%) No(%) No(%) No(%) No(%) 
No 
Complaint 
92(70.8) 88(68.2) 55(45.8) 70(69.3) 
78(83.0
) 
P/V 
Spotting 
4(3.1) 2(1.6) 4(3.3) 2(2.0) 1(1.1) 
Irregular 
menses 
0(0.0) 4(3.1) 10(8.3) 4(4.0) 4(4.3) 
Heavy 
menstrual 
Bleeding 
10(7.7) 18(14.0) 16(13.3) 8(7.9) 2(2.1) 
Amenorrho
ea 
1(0.8) 2(1.6) 4(3.3) 0(0.0) 0(0.0) 
Vaginal 
Discharge 
2(1.5) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
Change of 
Appetite / 
Dyspepsia 
10(7.7) 4(3.1) 2(1.7) 4(4.0) 0(0.0) 
Weight 
gain 
10(7.7) 2(1.6) 12(10.0) 4(4.0) 4(4.3) 
Reported 
Pregnancy 
0(0.0) 0(0.0) 0(0.0) 0(0.0) 
0 
0.0 
Lost 1(0.8) 3(2.3) 3(2.5) 4(4.0) 0(0.0) 
Removed 0(0.0) 6(4.7) 14(11.7) 5(5.0) 5(5.3) 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: Method continuation over study period  
 
Table 5: Reason for discontinuation Levonorgestrel 
SDI (n= 30) 
Reason Frequency Percentage 
Planning next pregnancy 05 16% 
Menstrual problems 18 60% 
Medical reasons 01 3.3% 
Weight gain  03 10% 
Gastric problems 03 10% 
Social reasons -- -- 
Reported pregnancy -- -- 
Discussion 
Unwanted and unintended pregnancies are major 
cause of maternal morbidity and mortality in terms of 
induced abortions, social problems and uncontrolled 
medical diseases like severe anaemia, diabetes and 
hypertension.This grave problem can only be solved if 
these women are advised appropriate and effective 
contraceptive method.Pakistan being a developing 
country needs LARC (long acting reversible 
contraceptives) to be included in public welfare 
programs. Levonorgestrel SDI are on WHOlist of 
essential medicine as most effective and safe medicine 
needed for health care system . 8This method is highly 
effective birth control method with one year failure 
rate of 0.05.9,10 This is consistent with our study where 
no pregnancy was reported during implant use. Also it 
was acceptable by women of all parities. 
In Pakistan use of Levonorgestrel SDI is nearly 1% 
according to statistics provided by Marie Stopes 
Society, Pakistan.11We wanted to determine the reason 
of acceptability of levonorgestrel SDI, in our study. 
Majority (42%) users opted for the method on doctors’ 
advice, hence health care providers play important 
role in helping women’s decision making. Similar 
results were shown by a study carried  at Family 
Planning Centre of Liaquat University Hospital.12 But 
majority of women 44% who opted for the method, 
made their own choice based on media and social 
information.These findings were inconsistent with an 
international study carried out in Greece, Germany 
and Turkey stating that women’s decision regarding 
family planning method is influenced more by family 
members and health care provider.13We found out that 
if media campaigns, information leaflets and lectures 
are designed keeping in view cultural, religious and 
economic factors. They are highly effective in 
promoting the use and continuity . 
Different side effects were reported by Levonorgestrel 
SDI users. In USA even lawsuits were filed against the 
manufacturer and the doctors who prescribed the 
method. 14In our study the most intolerable side effects 
reported were irregular menstrual bleeding, weight 
gain. Less common effects were headache, 
nausea,dyspepsia and feeling of weight gain. 
Implanon, a SDI consisting a single match stick size 
rod containing etonogestrel, now it has been replaced 
by Naxplanon .15Implanon users also reported side 
effects e.g. irregular menstrual bleeding, breast 
tenderness, loss of libido, headache and mood 
changes.16 Severity of this side effect was not 
emphasized in previous studies by Azmat SK, 
Bahamondes L, and Ali M. 11,17,18 We found out that 
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most common side effect was irregular menstrual 
bleeding but its frequency was higher than reported by 
previous studies 18.7%). 17,18  In most women it was 
not so heavy so as to cause medical problems like 
anaemia but had serious religious and social impact, 
this is consistent with a multicentre study carried by 
Population Welfare department Sind. 11 The affected 
women were unable to perform prayer regularly or 
maintain fast.They were unable to have desired sexual 
relationship due to irregular vaginal bleeding which 
caused marital discord. Demographic features, 
religious beliefs and husband and wife 
communications greatly influence the choice and 
continuation of family planning method. 19 We also 
experienced that most women who were willing for 
medical treatment with tranexamic acid and cyclical 
progestogens did not respond well to this treatment 
and ultimately got the implant removed. 
 
Conclusion 
1. Levonorgestrel SDI is a convenient, effective and 
acceptable long term reversible contraceptive 
method for our population. 
2. Services provided by trained health care provider 
with good clinical judgment increases acceptability 
of the method.  
3. Menstrual disturbances is major side effect and its 
incidence is higher than reported in previous 
studies. Intolerance to irregular and heavy menses 
was the most common reason which compelled 
users to discontinue this method.  
4.  Regular follow up is important because early 
recognition of users’ problems, timely education 
and treatment improves long term adherence of 
the method.   
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